BFM
CBAY

Boothbay Fund Management’s Cymabay Therapeutics CBAY Stock Holding History

Boothbay Fund Management’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-17,400
Closed -$259K – 2093
2023
Q3 		$259K Buy
+17,400
New +$231K 0.01% 1316

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Boothbay Fund Management's CBAY Position: Q4 2023 in Review

Boothbay Fund Management sold out of Cymabay Therapeutics (CBAY) in Q4 2023, closing a stake of 21,582 shares — an estimated $322K sold.

Boothbay Fund Management first reported a position in CBAY in Q3 2015 and held it in 9 quarters. The position peaked at $557K in Q2 2020. 200 funds tracked by Wall St. Rank hold CBAY as of Q4 2023.

  • Boothbay Fund Management reported no remaining Cymabay Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Boothbay Fund Management sold 21,582 Cymabay Therapeutics shares in Q4 2023, an estimated $322K.
  • Boothbay Fund Management first reported a position in Cymabay Therapeutics in Q3 2015 and held it in 9 quarters.
  • Boothbay Fund Management's Cymabay Therapeutics position peaked at $557K in Q2 2020.
  • 200 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q4 2023.

Based on Boothbay Fund Management's 13F filing for Q4 2023, filed 14 Feb 2024.